{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:33:53Z","timestamp":1786991633474,"version":"build-2736575974"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100017959","name":"Health Commission of Hebei Province","doi-asserted-by":"publisher","award":["20221476"],"award-info":[{"award-number":["20221476"]}],"id":[{"id":"10.13039\/100017959","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jchromb.2025.124529","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T14:32:12Z","timestamp":1740061932000},"page":"124529","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Improved analysis HPLC-ESI\/triple method for mapping the methotrexate by mass spectrometry"],"prefix":"10.1016","volume":"1255","author":[{"given":"Haihong","family":"Jia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruihong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiujuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jchromb.2025.124529_bb0005","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1182\/blood-2015-12-685586","article-title":"Some observations on the effect of folic acid antagonists on acute leukemia and other forms of incurable cancer. Blood. 1949;4(2):160\u2013167[J]","volume":"127","author":"Farber","year":"2016","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jchromb.2025.124529_bb0010","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21103483","article-title":"Overview of dual-acting drug methotrexate in different neurological diseases, autoimmune pathologies and cancers","volume":"21","author":"Ko\u017ami\u0144ski","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.jchromb.2025.124529_bb0015","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/FTD.0000000000000515","article-title":"Therapeutic drug monitoring of methotrexate in plasma using ultra high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry: necessary after Administration of Glucarpidase in methotrexate intoxications","volume":"40","author":"Mulder","year":"2018","journal-title":"Ther. Drug Monit."},{"issue":"7","key":"10.1016\/j.jchromb.2025.124529_bb0020","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1136\/ard.2008.093690","article-title":"Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research","volume":"68","author":"Salliot","year":"2009","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.jchromb.2025.124529_bb0025","first-page":"225","article-title":"Methotrexate: implications of pharmacogenetics in the treatment of patients with rheumatoid arthritis","volume":"1","author":"Torres","year":"2022","journal-title":"ARP Rheumatol"},{"issue":"6","key":"10.1016\/j.jchromb.2025.124529_bb0030","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/anr.1780320603","article-title":"Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment","volume":"32","author":"Alarc\u00f3n","year":"1989","journal-title":"Arthritis Rheum."},{"issue":"7","key":"10.1016\/j.jchromb.2025.124529_bb0035","doi-asserted-by":"crossref","DOI":"10.3390\/nu15071586","article-title":"Weekly folic acid is a convenient and well-tolerated alternative to daily dosing in pediatric patients with inflammatory bowel disease on methotrexate","volume":"15","author":"Temtem","year":"2023","journal-title":"Nutrients"},{"issue":"3","key":"10.1016\/j.jchromb.2025.124529_bb0040","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.30831","article-title":"Methotrexate level discrepancy post-glucarpidase: a pediatric case series and review of literature","volume":"71","author":"Kibby","year":"2024","journal-title":"Pediatr. Blood Cancer"},{"issue":"5","key":"10.1016\/j.jchromb.2025.124529_bb0045","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/j.jpba.2006.12.034","article-title":"Determination of methotrexate and its major metabolite 7-hydroxymethotrexate in mouse plasma and brain tissue by liquid chromatography-tandem mass spectrometry","volume":"43","author":"Guo","year":"2007","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"11","key":"10.1016\/j.jchromb.2025.124529_bb0050","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1080\/14740338.2019.1662395","article-title":"The role of therapeutic drug monitoring in the management of safety of anticancer agents: a focus on 3 cytotoxics","volume":"18","author":"Lev\u00eaque","year":"2019","journal-title":"Expert Opin. Drug Saf."},{"issue":"12","key":"10.1016\/j.jchromb.2025.124529_bb0055","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1634\/theoncologist.2015-0164","article-title":"Preventing and managing toxicities of high-dose methotrexate","volume":"21","author":"Howard","year":"2016","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.jchromb.2025.124529_bb0060","article-title":"Methotrexate for juvenile idiopathic arthritis[J]","volume":"2","author":"Tan","year":"2024","journal-title":"Cochrane Database Syst. Rev."},{"issue":"7","key":"10.1016\/j.jchromb.2025.124529_bb0065","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1002\/art.30367","article-title":"High prevalence of methotrexate intolerance in juvenile idiopathic arthritis: development and validation of a methotrexate intolerance severity score","volume":"63","author":"Bulatovi\u0107","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jchromb.2025.124529_bb0070","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12969-015-0052-6","article-title":"The experience of taking methotrexate for juvenile idiopathic arthritis: results of a cross-sectional survey with children and young people","volume":"13","author":"Mulligan","year":"2015","journal-title":"Pediatr. Rheumatol. Online J."},{"issue":"5","key":"10.1016\/j.jchromb.2025.124529_bb0075","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s40272-024-00643-9","article-title":"Methotrexate intolerance in juvenile idiopathic arthritis: definition, risks, and management","volume":"26","author":"Wibrand","year":"2024","journal-title":"Paediatr. Drugs"},{"issue":"25","key":"10.1016\/j.jchromb.2025.124529_bb0080","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1200\/JCO.2009.25.4540","article-title":"Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome","volume":"28","author":"Widemann","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"06","key":"10.1016\/j.jchromb.2025.124529_bb0085","first-page":"455","article-title":"Pharmaceutical monitoring of a patient with drug-induced liver injury caused by methotrexate by a clinical pharmacist","volume":"28","author":"Wen","year":"2019","journal-title":"Chin J Clin Pharm"},{"key":"10.1016\/j.jchromb.2025.124529_bb0090","unstructured":"Wu Z, Ding T, Qiu X, et.al. Pharmaceutical monitoring of a patient with kidney injury caused by high-dose methotrexate by a clinical pharmacist. Chin J Clin Pharm, 2020, 29(05): 385\u2013388."},{"issue":"2","key":"10.1016\/j.jchromb.2025.124529_bb0095","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/ipd.12718","article-title":"Oral mucositis in childhood cancer patients receiving high-dose methotrexate: prevalence, relationship with other toxicities and methotrexate elimination","volume":"31","author":"Valer","year":"2021","journal-title":"Int. J. Paediatr. Dent."},{"key":"10.1016\/j.jchromb.2025.124529_bb0100","unstructured":"Lin L, Zhong L, Chen J, et.al. Monitoring of methotrexate blood concentration and analysis of adverse reactions in pediatrics at our hospital. Int. J. Paediatr. Dent., 2018, 27(05): 329\u2013333."},{"issue":"9700","key":"10.1016\/j.jchromb.2025.124529_bb0105","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/S0140-6736(09)61416-1","article-title":"High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial","volume":"374","author":"Ferreri","year":"2009","journal-title":"Lancet"},{"issue":"02","key":"10.1016\/j.jchromb.2025.124529_bb0110","first-page":"357","article-title":"Comparative analysis of three detection methods for measuring methotrexate blood concentration","volume":"18","author":"Zhang","year":"2014","journal-title":"Anhui Pharm."},{"key":"10.1016\/j.jchromb.2025.124529_bb0115","unstructured":"Zhu L, Yang L, Zhao Z, et.al. Correlation study of FPIA method and HPLC-MS\/MS method for determination of methotrexate blood concentration. Zhongnan Pharm., 2015, 13(11): 1146\u20131150."},{"issue":"04","key":"10.1016\/j.jchromb.2025.124529_bb0120","first-page":"237","article-title":"Establishment and optimization of HPLC method for determination of methotrexate serum concentration","volume":"24","author":"Zhang","year":"2015","journal-title":"Chin J Clin Pharm"},{"key":"10.1016\/j.jchromb.2025.124529_bb0125","unstructured":"Dong W, Zhao X, Zhang X, et.al. Determination of methotrexate concentration in human plasma by HPLC-MS\/MS method. Chin J Clin Pharmacol, 2021, 37(14): 1874\u20131877."},{"issue":"1","key":"10.1016\/j.jchromb.2025.124529_bb0130","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.22157","article-title":"Comparison of LC-MS\/MS vs chemiluminescent microparticle immunoassay in measuring the valproic acid concentration in plasma of epilepsy patients in a new perspective","volume":"32","author":"Wang","year":"2018","journal-title":"J. Clin. Lab. Anal."},{"issue":"1\u20132","key":"10.1016\/j.jchromb.2025.124529_bb0135","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0378-4347(01)00402-9","article-title":"Separation methods for methotrexate, its structural analogues and metabolites","volume":"764","author":"Rubino","year":"2001","journal-title":"J. Chromatogr. B Biomed. Sci. Appl."},{"key":"10.1016\/j.jchromb.2025.124529_bb0140","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/1536532","article-title":"Simultaneous quantification of methotrexate and its metabolite 7-Hydroxy-methotrexate in human plasma for therapeutic drug monitoring[J]","volume":"2019","author":"Ren","year":"2019","journal-title":"Int J Anal Chem"},{"issue":"6","key":"10.1016\/j.jchromb.2025.124529_bb0145","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1039\/C4AN02321H","article-title":"A HPLC-SRM-MS based method for the detection and quantification of methotrexate in urine at doses used in clinical practice for patients with rheumatological disease: a potential measure of adherence","volume":"140","author":"Bluett","year":"2015","journal-title":"Analyst"},{"key":"10.1016\/j.jchromb.2025.124529_bb0150","unstructured":"Hu N, Qian Q, Hui Q, et.al. LC-MS\/MS method for detecting the concentration of methotrexate and its metabolite 7-hydroxymethotrexate in the serum of patients with hematological malignancies. China Pharm, 2020, 23(05): 910\u2013913."},{"key":"10.1016\/j.jchromb.2025.124529_bb0155","doi-asserted-by":"crossref","first-page":"4575","DOI":"10.2147\/DDDT.S335122","article-title":"A validated HPLC-MS\/MS method for quantification of methotrexate and application for therapeutic drug monitoring in children and adults with non-Hodgkin lymphoma","volume":"15","author":"Feng","year":"2021","journal-title":"Drug Des. Devel. Ther."}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023225000819?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023225000819?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T16:04:21Z","timestamp":1741017861000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023225000819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":31,"alternative-id":["S1570023225000819"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2025.124529","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improved analysis HPLC-ESI\/triple method for mapping the methotrexate by mass spectrometry","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2025.124529","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"124529"}}